Non-Invasive Prenatal Testing Market
完整報告名稱與涵蓋範圍
Non-Invasive Prenatal Testing Market Size, Share & Trends Analysis Report, By Gestation Period (0-12 Weeks, 13-24 Weeks, 25-36 Weeks), By Pregnancy Risk (High & Average Risk, Low Risk), By Method (Ultrasound Detection, Biochemical Screening Tests, Cell-Free DNA in Maternal Plasma Tests), By Technology, By Product, By Application, By End-User, By Region, Forecasts, 2024-2031
報告摘要
In 2023, the Non-Invasive Prenatal Testing Market worldwide was assessed at USD 4.63 billion. Analysts project it will accelerate to USD 12.20 billion by 2031, at a CAGR of 13.02% spanning 2024 to 2031.
The Non-Invasive Prenatal Testing sector involves a method for determining the likelihood that a fetus will have genetic abnormalities. This domain has witnessed substantial transformation owing to technological breakthroughs and shifting healthcare dynamics.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the mounting emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold substantial shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and mounting investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-Invasive Prenatal Testing Market Snapshot
Chapter 4. Global Non-Invasive Prenatal Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Gestation Period Estimates & Trend Analysis
5.1. by Gestation Period & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Gestation Period:
5.2.1. 0-12 Weeks
5.2.2. 13-24 Weeks
5.2.3. 25-36 Weeks
Chapter 6. Market Segmentation 2: by Pregnancy Risk Estimates & Trend Analysis
6.1. by Pregnancy Risk & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Pregnancy Risk:
6.2.1. High & Average Risk
6.2.2. Low Risk
Chapter 7. Market Segmentation 3: by Method Estimates & Trend Analysis
7.1. by Method & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Method:
7.2.1. Ultrasound Detection
7.2.2. Biochemical Screening Tests
7.2.3. Cell-Free DNA in Maternal Plasma Tests
Chapter 8. Market Segmentation 4: by Technology Estimates & Trend Analysis
8.1. by Technology & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Technology:
8.2.1. NGS
8.2.2. Array Technology
8.2.3. PCR
8.2.4. Others
Chapter 9. Market Segmentation 5: by Product Estimates & Trend Analysis
9.1. by Product & Market Share, 2019 & 2031
9.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product:
9.2.1. Consumables & Reagents
9.2.2. Instruments
Chapter 10. Market Segmentation 6: by Application Estimates & Trend Analysis
10.1. by Application & Market Share, 2019 & 2031
10.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
10.2.1. Trisomy
10.2.2. Microdeletion Syndrome
10.2.3. Other Applications
Chapter 11. Market Segmentation 7: by End-Use Estimates & Trend Analysis
11.1. by End-Use & Market Share, 2019 & 2031
11.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-Use:
11.2.1. Hospitals & Clinics
11.2.2. Diagnostic Laboratories
Chapter 12. Non-Invasive Prenatal Testing Market Segmentation 3: Regional Estimates & Trend Analysis
12.1. North America
12.1.1. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.1.2. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.1.3. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.1.4. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.1.5. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.1.6. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.1.7. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.1.8. North America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.2. Europe
12.2.1. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.2.2. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.2.3. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.2.4. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.2.5. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.2.6. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.2.7. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.2.8. Europe Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.3. Asia Pacific
12.3.1. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.3.2. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.3.3. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.3.4. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.3.5. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.3.6. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.3.7. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.3.8. Asia Pacific Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.4. Latin America
12.4.1. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.4.2. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.4.3. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.4.4. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.4.5. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.4.6. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.4.7. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.4.8. Latin America Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
12.5. Middle East & Africa
12.5.1. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Gestation Period, 2024-2031
12.5.2. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Pregnancy Risk, 2024-2031
12.5.3. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Method, 2024-2031
12.5.4. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
12.5.5. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
12.5.6. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
12.5.7. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by End-Use, 2024-2031
12.5.8. Middle East & Africa Non-Invasive Prenatal Testing Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 13. Competitive Landscape
13.1. Major Mergers and Acquisitions/Strategic Alliances
13.2. Company Profiles
13.2.1. Genesis Genetics (CooperSurgical, Inc.)
13.2.2. Natera, Inc.
13.2.3. Eurofins LifeCodexx GmbH
13.2.4. Illumina, Inc. (Verinata Health, Inc.)
13.2.5. Centogene N.V.
13.2.6. MedGenome Labs Ltd.
13.2.7. Myriad Women's Health, Inc. (Counsyl, Inc.)
13.2.8. F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
13.2.9. Qiagen
13.2.10. Laboratory Corp. of America Holdings
13.2.11. Progenity, Inc.
13.2.12. Quest Diagnostics, Inc.
13.2.13. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們